ENSHAN HONG is a Partner at VLP and a member of the firm’s Intellectual Property Practice Group. Enshan currently focuses his practice on preparation of opinions on patent validity, infringement, and freedom-to-operate issues; conducting due diligence investigations; counseling clients on issues related to the Hatch-Waxman Act; prosecuting patent applications; and representing clients in re-examination, reissue, and patent term extension proceedings. He was also involved in a number of patent litigations in his previous firm.
Enshan counsels a diverse group of clients ranging from individual inventors to multinational corporations. His practice covers various technologies, including chemical compounds and processes, pharmaceutical formulations, herbal extracts, cosmetic products, nutritional supplements, medical treatment and diagnosis, medical devices, polymers, tires, food processing, petroleum processing, catalysts, inkjet inks, business method, internet, software, and semiconductor materials. Enshan’s practice also includes trademark, copyright, unfair competition, trade secret, right of privacy & right of publicity, business immigration, and corporate.
Prior to joining VLP, Enshan practiced at Cozen O’Connor, one of the top 100 general practice law firms in the country. Before joining Cozen O’Connor, Enshan was with Cohen Pontani Lieberman & Pavane, one of New York City’s leading IP boutique firms, from 2002-2011. Enshan began his legal career in 1996 with a Fortune 500 company, China Petroleum and Chemical Corporation (Sinopec), where his practice focused on intellectual property management, patent prosecution, patent validity, infringement, enforcement analysis, and patent strategy. He also worked for five years as a chemical engineer in Scinopec before becoming a patent attorney and is fluent in Mandarin Chinese.
- J.D., Rutgers University School of Law, 2008
- M.I.P. (Master of Intellectual Property Law), Franklin Pierce Law Center, 2002
- B.S., China University of Petroleum, 1991
- Inter parties rexamination on behalf of Gladerma R&D of Leo Pharmaceutical Products Ltd., US Patent No. 6,753,013 for TACLONEX (August 2008)
- In re Metoprolol Succinate Patent Litigation, No. 2006-1254 (Fed. Cir. July 23, 2007).
- Pharm. Res., Inc. v. Roxane Labs. Inc., No. 03-3357, 2006 U.S. Dist. LEXIS 81628, 2006 WL 3231427 (D.N.J. Nov. 8, 2006).
- Dey LP v. IVAX Pharm. Inc., 233 F.R.D. 567 (C.D. Cal. 2005).
- Author, “Practice Tips of Drafting The Background Section of A U.S. Patent Application,” China Patent Agency, 2012 (1).
- Author, “An Important Intellectual Property Issue to Consider Prior to Entering the U.S. Market,” Global Chinese Weekly (August 2012).
- Lecturer/Author, “Patent Freedom-to-Operate Opinion,” Beijing Intellectual Property Protection Association, Beijing, China (April 2012).
- Lecturer/Author, “Leahy-Smith America Invents Act and Freedom-to-Operate,” SINOPEC Research Institute of Petroleum Processing (RIPP), Beijing, China (April 2012).
- Author, “Practicing the Prior Art under Chinese Patent Law”, INVENTION & INNOVATION 2010 (3).
- Co-author, “Analysis of Selection Invention with Examples,” INVENTION & INNOVATION 2003 (7).
- Co-author, “Analysis of Selection Invention,” INVENTION & INNOVATION 2003 (2).
- Co-author, “Novelty and Inventiveness of Invention Patent,” INVENTION & INNOVATION 2001 (1).
State Bar of New York
United States Patent and Trademark Office